IDEAS home Printed from https://ideas.repec.org/a/sae/medema/v14y1994i1p52-58.html
   My bibliography  Save this article

Determining Transition Probabilities

Author

Listed:
  • Douglas K. Miller
  • Sharon M. Homan

Abstract

Confusion regarding proper use of the terms rate and risk persists in the literature. This has implications for the proper modeling of prognosis and transition between health states in decision analysis and related techniques. The issue is complicated by the plethora of terms related to rate and risk. Although the suggestion to use the terms force and probability as substitutes for rate and risk has some appeal, the change in terminology by itself is unlikely to solve all the confusion or misuse of terms. This paper clarifies the proper definitions and estimations of rates and risks and suggests critical factors for the decision analyst to re member when using, modeling, or interpreting transition rates and risks. Key words: decision models; rate; risk; force; probability; transitions. (Med Decis Making 1994;14:52-58)

Suggested Citation

  • Douglas K. Miller & Sharon M. Homan, 1994. "Determining Transition Probabilities," Medical Decision Making, , vol. 14(1), pages 52-58, February.
  • Handle: RePEc:sae:medema:v:14:y:1994:i:1:p:52-58
    DOI: 10.1177/0272989X9401400107
    as

    Download full text from publisher

    File URL: https://journals.sagepub.com/doi/10.1177/0272989X9401400107
    Download Restriction: no

    File URL: https://libkey.io/10.1177/0272989X9401400107?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. K. Le Lay & E. Myon & S. Hill & L. Riou-Franca & D. Scott & M. Sidhu & D. Dunlop & R. Launois, 2007. "Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 145-151, June.
    2. Bruce A. Craig & Peter P. Sendi, 2002. "Estimation of the transition matrix of a discrete‐time Markov chain," Health Economics, John Wiley & Sons, Ltd., vol. 11(1), pages 33-42, January.
    3. Jan Jürgensen & Robert Ikenberg & Roger-Axel Greiner & Volker Hösel, 2015. "Cost-effectiveness of modern mTOR inhibitor based immunosuppression compared to the standard of care after renal transplantation in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(4), pages 377-390, May.
    4. Rachael Fleurence & Christopher Hollenbeak, 2007. "Rates and Probabilities in Economic Modelling," PharmacoEconomics, Springer, vol. 25(1), pages 3-6, January.
    5. Francesco Saverio Mennini & Simone Russo & Andrea Marcellusi & Giuseppe Quintaliani & Denis Fouque, 2013. "Economic effects of treatment of chronic kidney disease with low-protein diet," CEIS Research Paper 292, Tor Vergata University, CEIS, revised 10 Oct 2013.
    6. Lartey, Stella T. & Si, Lei & Otahal, Petr & de Graaff, Barbara & Boateng, Godfred O. & Biritwum, Richard Berko & Minicuci, Nadia & Kowal, Paul & Magnussen, Costan G. & Palmer, Andrew J., 2020. "Annual transition probabilities of overweight and obesity in older adults: Evidence from World Health Organization Study on global AGEing and adult health," Social Science & Medicine, Elsevier, vol. 247(C).
    7. Thomas Hoffmann & Helmut Brunner, 2004. "Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(2), pages 129-135, May.
    8. Nicola J. Cooper & Alex J. Sutton & Keith R. Abrams & David Turner & Allan Wailoo, 2004. "Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach," Health Economics, John Wiley & Sons, Ltd., vol. 13(3), pages 203-226, March.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:sae:medema:v:14:y:1994:i:1:p:52-58. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: SAGE Publications (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.